Resverlogix Q&A From TodayI asked a few clarification questions today of RVX. Here is a summary of the Q&A, which is not transcribed verbatim: 1. QUESTION: In Don's last webcast, I think it was on the 2nd to the last slide, he mentioned various potential Phase 3 trials - PAD, Kidney Disease, and an Orphan Indication. These in addition to reMACE for diabetes. My question is whether these potential trials are being talked about as separate Phase 3 trials or as sub-parts of reMACE.
ANSWER: To clarify the trial will be called BETonMACE. In the BETonMACE trial Don mentioned that by default approximately 15% of the patients will have CKD so this will be examined in the BETonMACE trial. A PAD and Orphan indication would be separate small trials. If you listen back to the BIO CEO webcast we do believe this is clear.
2. QUESTION: Assuming some or all of these other Phase 3 trials are separate from reMACE, is funding in place for these trials?
ANSWER: We have access to capital required for these clinical trials.
3. QUESTION: When is the next Webcast for Resverlogix expected to be?
ANSWER: The BIO CEO webcast from last month is still current. Our goal is to have an updated webcast every quarter, unless there is new information then we will webcast accordingly.